Comparative characteristics of the incidence of various endocrinopathies in cancer patients receiving treatment with immune checkpoint inhibitors

Zhurtova I.B., Aramisova L.S., Abdul Moati H.A., Arkhestova D.R., Khachmakhova E.Z.

Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov, Nalchik, Russia

To date, there are at least 6 national and international guidelines for the management of endocrine complications associated with the use of immune checkpoint inhibitors (ICPIs). This article is a summary of the latest guidelines developed by a number of scientists on behalf of the European Society of Endocrinology (ESE). The article presents possible endocrine complications during therapy with anti-CTLA-4, anti-PD-1, anti-PD-L1 drugs and combination treatment with ipilimumab and nivolumab. Combination treatment with ICPIs with chemotherapy or targeted therapy is not discussed in the guidelines and article.

Keywords

About the Authors

Corresponding author: Inessa B. Zhurtova, Dr. Sci. (Med.), Professor at the Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University named after Kh.M. Berbekov, Nalchik, Russia; zhin07@mail.ru

Similar Articles